NCT04124991View on ClinicalTrials.gov

Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 12, 2020

Primary Completion Date

July 6, 2022

Study Completion Date

July 28, 2022

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Durvalumab

Radioembolization with Yttrium-90 Microspheres

RADIATION

Radioembolization

Radioembolization with Yttrium-90 Microspheres

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT04124991 - Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC | Biotech Hunter | Biotech Hunter